Author: Ravi Shankar

MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) — Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Emerging Growth Conference on Wednesday 28^th October 2026 (4:25pm – 4:55pm U.S. Eastern Time).

Please submit your questions in advance to Questions@EmergingGrowth.com or ask your questions during the event.

Please register here to ensure you are able to attend the conference and receive any updates that are released.

https://goto.webcasts.com/starthere.jsp?ei=1772210&tp_key=8ae90219a3&sti=imrn

This release has been authorised by the directors of Immuron Limited.

COMPANY CONTACT: Steven Lydeamore Chief Executive Officer steve@immuron.com

About Immuron
Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases.

About Travelan®

Travelan® is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers’ diarrhea. In Australia, Travelan® is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travelers’ Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan® is a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers’ Diarrhea. In the U.S., Travelan® is sold as a dietary supplement for digestive tract protection.

Travelers’ diarrhea (TD)
TD is generally defined as the passage of ≥ 3 unformed stools per 24 hours plus at least one additional symptom (such as nausea, vomiting, abdominal cramps, fever, blood/mucus in the stools, or fecal urgency) that develop while abroad or within 10 days of returning from any resource-limited destinations (Leung et al., 2006). Diarrhea continues to be the most frequent health problem among travelers to destinations in lower- and middle-income regions (Steffen, 2017). Deployed US military personnel, essentially representing a long-term traveller population, are particularly affected given their population dynamics and the context in which they seek care and treatment (Connor et al., 2012). Diarrhea is the leading infectious disease threat to the overall health and preparedness of deployed US armed forces, with diarrheagenic E. coli, Campylobacter spp., and Shigella spp. among the most commonly reported etiologies (Riddle et al., 2006).

Immuron Platform Technology

Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its full benefits directly to the bacteria found there. The underlying nature of Immuron’s platform technology enables the development of medicines across a large range of infectious diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such as the Gastrointestinal tract and neutralize the toxins they produce.

IMM-124E (Travelan®)

IMM-124E was developed using Immuron’s platform technology. IMM-124E is produced from the colostrum of birthing cattle that have been immunised during pregnancy with a vaccine containing the outer antigens of multiple human derived ETEC. A total of 13 ETEC strains are used in the vaccine to produce high levels of antibodies against selected surface antigens from the most common strains of ETEC. (Otto et al., 2011)

The resultant hyperimmune colostrum IMM-124E from ETEC vaccinated cows contains significant levels of polyclonal antibodies specific for ETEC antigens LPS, CFA-I and Flagellin (Sears et al., 2017).

The antibodies produced in IMM-124E have been found to have a stronger binding and neutralizing activity (than the antibodies of unvaccinated cattle) against a wide range of LPS antigens including both the variable O-polysaccharide region and the preserved oligosaccharide core ‘R’ region of LPS from the 13 serotypes used in the ETEC vaccine.

IMM-124E is manufactured into a tablet form referred to as Travelan®.

IMM-529
Immuron is developing IMM-529 as an adjunctive therapy in combination with standard of care antibiotics for the prevention and/or treatment of recurrent Clostridioides difficile infection (CDI). IMM-529 antibodies targeting Clostridioides difficile (C. diff) may help to clear CDI infection and promote a quicker re-establishment of normal gut flora, providing an attractive oral preventative for recurrent CDI.

Immuron is collaborating with Dr. Dena Lyras and her team at Monash University, Australia to develop vaccines to produce bovine colostrum-derived antibodies. Dairy cows were immunised to generate hyperimmune bovine colostrum (HBC) that contains antibodies targeting three essential C. diff virulence components. IMM-529 targets Toxin B (TcB), the spores and the surface layer proteins of the vegetative cells.

This unique 3-target approach has yielded promising results in pre-clinical infection and relapse models, including (1) Prevention of primary disease (80% P =0.0052); (2) Protection of disease recurrence (67%, P <0.01) and (3) Treatment of primary disease (78.6%, P<0.0001; TcB HBC). Importantly IMM-529 antibodies cross-react with whole cell lysates of many different human strains of C. diff including hypervirulent strains.

To our knowledge, IMM-529 is, to date, the only investigational drug that has shown therapeutic potential in all three phases of the disease (Hutton et al., 2017).

ProIBS®
Immuron has an exclusive distribution agreement with Calmino goup AB for the territories of Australia and New Zealand for ProIBS®. ProIBS® – to help patients treat IBS symptoms ProIBS® is a certified medical device for the treatment of IBS symptoms such as abdominal pain, bloating and unsettled bowel movements (diarrhoea and/or constipation). ProIBS® contains AVH200®, derived from the plant Aloe barbadensis. Mill. AVH200® has gel forming components which support the intestinal mucosal barrier. As IBS is known to affect individuals for a long period of time, it is essential to have a treatment appropriate for long-term use –as ProIBS® is. The product is safe, and no interactions with other medications are known. Science-driven innovative Calmino group AB, the developer of ProIBS®, conducted a usability study among 1,003 users. PROIBS® was helpful for 94% of them. 91% of the users experienced an improvement in daily life and 98% would recommend PROIBS® to someone else. To learn more please check: www.proibs.eu.

Irritable bowel syndrome (IBS) is a common condition where you experience symptoms related to your digestive system. This is sometimes linked to certain foods, lifestyle habits and stress levels or mood. IBS affects around 3 out of every 10 people. Females are more likely than males to be affected. Some key symptoms of IBS include: abdominal pain or discomfort; stomach bloating and wind; chronic diarrhoea or constipation, or alternating between the two.(healthdirect.gov.au) According to available data, the IBS treatment market in Australia is estimated to be a part of the broader “Digestives & Intestinal Remedies” market, generating a revenue of around AU$221.14 million in 2025, with a projected annual growth rate of 3.28%.(Statista)

References

Connor P, Porter CK, Swierczewski B and Riddle MS. Diarrhea during military deployment: current concepts and future directions. Curr Opin Infect Dis. 25(5): 546-54; 2012.

Hutton, M.L., Cunningham, B.A., Mackin, K.E. et al. Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative. Sci Rep 7, 3665 (2017). https://doi.org/10.1038/s41598-017-03982-5

Leung AK, Robson WL, Davies HD. Travelers’ diarrhea. Adv Ther. Jul-Aug; 23(4): 519-27; 2006

Otto W, Najnigier B, Stelmasiak T and Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers Scandinavian Journal of Gastroenterology 46: 862– 868; 2011.

Riddle MS, Sanders JW, Putnam SD, and Tribble DR. Incidence, etiology, and impact of diarrhea among long-term travelers’ (US military and similar populations): A systematic review. American Journal of Tropical Medicine and Hygiene. 74(5): 891-900; 2006.

Sears KT, Tennant SM, Reymann MK, Simon R, Konstantopolos N, Blackwelder WC, Barry EM and Pasetti MF. Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum products. Clinical and Vaccine Immunology. 24 (8) 1-14; 2017.

Steffen R. Epidemiology of travelers’ diarrhea. J Travel Med. 24(suppl_1): S2-S5; 2017.

For more information visit: https://www.immuron.com.au/ and https://www.travelan.com
Subscribe to Immuron’s InvestorHub: Here

FORWARD-LOOKING STATEMENTS:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TORONTO, Oct. 22, 2026 (GLOBE NEWSWIRE) — Hercules Metals Corp. (TSXV: BIG | OTCQB: BADEF) (“Hercules” or the “Company“) is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. and BMO Capital Markets, as joint bookrunners, on behalf of a syndicate of underwriters (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a bought-deal private placement basis, 34,500,000 common shares of the Company (the “Common Shares”) at a price of $0.87 per Common Share (the “Offering Price”) for gross proceeds of $30,015,000 (the “Offering”).

The Company has also granted the Underwriters an option to purchase up to an additional 5,200,000 Common Shares at the Offering Price for additional gross proceeds of up to $4,524,000 exercisable, in whole or in part, at any time up to 48 hours prior to the closing of the Offering (the “Underwriter Option”).

The net proceeds of the Offering will be used to advance the Hercules Project, as well as for working capital and general corporate purposes.

The Common Shares will be offered by way of private placement pursuant to applicable exemptions from prospectus requirements in each of the provinces of Canada, other than Quebec, and in such other jurisdictions as may be mutually agreed between the Company and the Underwriters. It is anticipated that closing of the Offering will occur on or about November 12, 2026, or such other date or dates as the Company and the Underwriters may agree. The Offering is subject to the satisfaction of certain conditions, including receipt of all applicable regulatory approvals including the conditional approval of the TSX Venture Exchange. The securities to be issued under the Offering will be subject to a hold period expiring four months and one day from the applicable closing date in accordance with applicable Canadian securities laws.

About Hercules Metals Corp.

Hercules Metals Corp. (TSXV: BIG) (OTCQB: BADEF) is an exploration Company focused on developing America’s newest porphyry copper district, in Idaho.

The 100% owned Hercules Project, located northwest of Cambridge, hosts the Leviathan porphyry copper system, one of the most important new discoveries in the country to date. The Company is well positioned for growth through continued drilling, supported by a strategic investment from Barrick Mining Corporation.

With the potential for significant scale, the Company’s management and board of directors aims to deliver value to shareholders through proven discovery success.

For further information please contact:

George Ogilvie
President and CEO
Telephone +1 (416) 723-0458
Email: gogilvie@herculesmetals.com

Alison Dwoskin
VP Investor Relations
Telephone: +1 (647) 233-4348
Email: adwoskin@herculesmetals.com

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. Any securities referred to herein have not and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws of an exemption from such registration is available.

Cautionary Statements Regarding Forward-Looking Information

All statements, other than statements of historical fact, contained or incorporated by reference in this press release constitute “forward-looking statements” and “forward-looking information” (collectively, “forward-looking statements”) within the meaning of applicable Canadian and United States securities legislation. Generally, forward-looking statements can be identified by the use of forward-looking terminology such as “assumption”, “believe”, “developing”, “estimate”, “expectation”, “exploration”, “focused”, “forward”, “future”, “intended”, “may”, “potential”, “project”, and “will”, or variations of such words, and similar such words, expressions or statements that certain actions, events, conditions or results will, may, could, or should (or not) be achieved, occur, provide, result or support in the future, or which, by their nature, refer to future events. In some cases, forward-looking information may be stated in the present tense, such as in respect of current matters that may be continuing, or that may have a future impact or effect. Forward-looking statements in this press release may include statements regarding the Offering, the use of proceeds of the Offering, the ability to obtain necessary approvals in respect of the Offering, including the conditional approval of the TSX Venture Exchange.

Although the Company believes the forward-looking statements contained in this press release are reasonable, there can be no assurance that those forward-looking statements will prove to be correct, and any forward-looking statements by the Company are not guarantees of future actions, results or performance. Forward-looking statements are based on assumptions, estimates, expectations, information and opinions, which are considered reasonable and represent best judgment based on available facts, as of the issuance of this press release. If such assumptions, estimates, expectations and opinions prove to be incorrect, actual and future results may be materially different than expressed or implied in the forward-looking statements. The assumptions, estimates, expectations and opinions contained in this press release which may prove to be incorrect include those set forth in this press release, as well as those stated in the Company’s other public disclosure, including its Management’s Discussion and Analysis (together with the accompanying financial statements) for the year ended December 31, 2025 and for the most recently completed financial quarter (collectively, the “Public Disclosure”), available on the Company’s website at www.herculesmetals.com and under its issuer profile at www.sedarplus.ca. Forward-looking statements, by their nature, are inherently subject to known and unknown risks, uncertainties, contingencies and other factors which may cause the Company’s actual results, activity, performance, developments or achievements, or other future events, to be materially different from any future results, activity, performance, developments or achievements expressed or implied by such forward-looking statements. Examples of such assumptions, estimates, expectations, opinions, risks, uncertainties, contingencies and other factors include those identified herein as well as those set forth in the Public Disclosure, available on the Company’s website at www.herculesmetals.com and/or under its issuer profile at www.sedarplus.ca. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those contained in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are made as of the issuance of this press release (or as otherwise expressly specified) and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements referenced or contained in this press release are expressly qualified by these Cautionary Statements as well as the cautionary statements and/or notes in the Public Disclosure.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TORONTO, Oct. 22, 2026 (GLOBE NEWSWIRE) — Hercules Metals Corp. (TSXV: BIG | OTCQB: BADEF) (“Hercules” or the “Company“) is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. and BMO Capital Markets, as joint bookrunners, on behalf of a syndicate of underwriters (collectively, the “Underwriters”), pursuant to which the Underwriters have agreed to purchase, on a bought-deal private placement basis, 34,500,000 common shares of the Company (the “Common Shares”) at a price of $0.87 per Common Share (the “Offering Price”) for gross proceeds of $30,015,000 (the “Offering”).

The Company has also granted the Underwriters an option to purchase up to an additional 5,200,000 Common Shares at the Offering Price for additional gross proceeds of up to $4,524,000 exercisable, in whole or in part, at any time up to 48 hours prior to the closing of the Offering (the “Underwriter Option”).

The net proceeds of the Offering will be used to advance the Hercules Project, as well as for working capital and general corporate purposes.

The Common Shares will be offered by way of private placement pursuant to applicable exemptions from prospectus requirements in each of the provinces of Canada, other than Quebec, and in such other jurisdictions as may be mutually agreed between the Company and the Underwriters. It is anticipated that closing of the Offering will occur on or about November 12, 2026, or such other date or dates as the Company and the Underwriters may agree. The Offering is subject to the satisfaction of certain conditions, including receipt of all applicable regulatory approvals including the conditional approval of the TSX Venture Exchange. The securities to be issued under the Offering will be subject to a hold period expiring four months and one day from the applicable closing date in accordance with applicable Canadian securities laws.

About Hercules Metals Corp.

Hercules Metals Corp. (TSXV: BIG) (OTCQB: BADEF) is an exploration Company focused on developing America’s newest porphyry copper district, in Idaho.

The 100% owned Hercules Project, located northwest of Cambridge, hosts the Leviathan porphyry copper system, one of the most important new discoveries in the country to date. The Company is well positioned for growth through continued drilling, supported by a strategic investment from Barrick Mining Corporation.

With the potential for significant scale, the Company’s management and board of directors aims to deliver value to shareholders through proven discovery success.

For further information please contact:

George Ogilvie
President and CEO
Telephone +1 (416) 723-0458
Email: gogilvie@herculesmetals.com

Alison Dwoskin
VP Investor Relations
Telephone: +1 (647) 233-4348
Email: adwoskin@herculesmetals.com

This press release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. Any securities referred to herein have not and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws of an exemption from such registration is available.

Cautionary Statements Regarding Forward-Looking Information

All statements, other than statements of historical fact, contained or incorporated by reference in this press release constitute “forward-looking statements” and “forward-looking information” (collectively, “forward-looking statements”) within the meaning of applicable Canadian and United States securities legislation. Generally, forward-looking statements can be identified by the use of forward-looking terminology such as “assumption”, “believe”, “developing”, “estimate”, “expectation”, “exploration”, “focused”, “forward”, “future”, “intended”, “may”, “potential”, “project”, and “will”, or variations of such words, and similar such words, expressions or statements that certain actions, events, conditions or results will, may, could, or should (or not) be achieved, occur, provide, result or support in the future, or which, by their nature, refer to future events. In some cases, forward-looking information may be stated in the present tense, such as in respect of current matters that may be continuing, or that may have a future impact or effect. Forward-looking statements in this press release may include statements regarding the Offering, the use of proceeds of the Offering, the ability to obtain necessary approvals in respect of the Offering, including the conditional approval of the TSX Venture Exchange.

Although the Company believes the forward-looking statements contained in this press release are reasonable, there can be no assurance that those forward-looking statements will prove to be correct, and any forward-looking statements by the Company are not guarantees of future actions, results or performance. Forward-looking statements are based on assumptions, estimates, expectations, information and opinions, which are considered reasonable and represent best judgment based on available facts, as of the issuance of this press release. If such assumptions, estimates, expectations and opinions prove to be incorrect, actual and future results may be materially different than expressed or implied in the forward-looking statements. The assumptions, estimates, expectations and opinions contained in this press release which may prove to be incorrect include those set forth in this press release, as well as those stated in the Company’s other public disclosure, including its Management’s Discussion and Analysis (together with the accompanying financial statements) for the year ended December 31, 2025 and for the most recently completed financial quarter (collectively, the “Public Disclosure”), available on the Company’s website at www.herculesmetals.com and under its issuer profile at www.sedarplus.ca. Forward-looking statements, by their nature, are inherently subject to known and unknown risks, uncertainties, contingencies and other factors which may cause the Company’s actual results, activity, performance, developments or achievements, or other future events, to be materially different from any future results, activity, performance, developments or achievements expressed or implied by such forward-looking statements. Examples of such assumptions, estimates, expectations, opinions, risks, uncertainties, contingencies and other factors include those identified herein as well as those set forth in the Public Disclosure, available on the Company’s website at www.herculesmetals.com and/or under its issuer profile at www.sedarplus.ca. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those contained in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking statements contained herein are made as of the issuance of this press release (or as otherwise expressly specified) and the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or results or otherwise, except as required by applicable securities laws. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements referenced or contained in this press release are expressly qualified by these Cautionary Statements as well as the cautionary statements and/or notes in the Public Disclosure.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

CHARLOTTE, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) — Perimeter Solutions, Inc., rebranding to Perimeter Group Inc., (NYSE: PRM) (“Perimeter” or the “Company”), a leading provider of industrial products and services that support critical and complex customer missions across a range of niche applications, announced today it will release its financial results for the third quarter 2026 on Thursday, November 5, 2026, before the market opens.

The Company will host a conference call to discuss these results at 8:30 a.m. ET on the same day. The presentation will be led by CEO Haitham Khouri, CFO Kyle Sable, and Head of Investor Relations Seth Barker.

The live webcast of the call can be accessed through Perimeter’s investor relations website at https://ir.perimetergroup.com/ and as follows:

When: Thursday, November 5, 2026, at 8:30 AM (ET)

Dial-in Number and Meeting ID: 800-420-1459 / 203-518-9861 Conference ID: PRMQ326

Conference Name: Perimeter Group Q3 2026 Earnings Call

Materials Available At: https://ir.perimetergroup.com/

Replay Available: Thursday, November 5, 2026 to November 4, 2027 (11:59 PM ET)

Internet Access: https://event.on24.com/wcc/r/5455901/DE65A091E6E7F8F26AD7EF2403B8FCF8

About Perimeter

Perimeter is a leading provider of industrial products and services that support critical and complex customer missions across a range of niche applications. It comprises six market-leading businesses across two reporting segments: Fire Safety (Perimeter Solutions, Solberg Fire, and Monaco Enterprises) and Specialty Products (PDI, MMT, and IMS). Perimeter prioritizes serving its customers’ needs while driving private-equity-like returns, all enabled by its Operational Value Drivers model and decentralized operating structure. Perimeter reinvests in its businesses to strengthen the products and services they provide to customers, and it expects to continue growing organically and through value-creating acquisitions.

Investor Relations Contact:

Seth Barker
Head of Investor Relations and VP of Financial Planning and Analysis
ir@perimetergroup.com

CHARLOTTE, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) — Perimeter Solutions, Inc., rebranding to Perimeter Group Inc., (NYSE: PRM) (“Perimeter” or the “Company”), a leading provider of industrial products and services that support critical and complex customer missions across a range of niche applications, announced today it will release its financial results for the third quarter 2026 on Thursday, November 5, 2026, before the market opens.

The Company will host a conference call to discuss these results at 8:30 a.m. ET on the same day. The presentation will be led by CEO Haitham Khouri, CFO Kyle Sable, and Head of Investor Relations Seth Barker.

The live webcast of the call can be accessed through Perimeter’s investor relations website at https://ir.perimetergroup.com/ and as follows:

When: Thursday, November 5, 2026, at 8:30 AM (ET)

Dial-in Number and Meeting ID: 800-420-1459 / 203-518-9861 Conference ID: PRMQ326

Conference Name: Perimeter Group Q3 2026 Earnings Call

Materials Available At: https://ir.perimetergroup.com/

Replay Available: Thursday, November 5, 2026 to November 4, 2027 (11:59 PM ET)

Internet Access: https://event.on24.com/wcc/r/5455901/DE65A091E6E7F8F26AD7EF2403B8FCF8

About Perimeter

Perimeter is a leading provider of industrial products and services that support critical and complex customer missions across a range of niche applications. It comprises six market-leading businesses across two reporting segments: Fire Safety (Perimeter Solutions, Solberg Fire, and Monaco Enterprises) and Specialty Products (PDI, MMT, and IMS). Perimeter prioritizes serving its customers’ needs while driving private-equity-like returns, all enabled by its Operational Value Drivers model and decentralized operating structure. Perimeter reinvests in its businesses to strengthen the products and services they provide to customers, and it expects to continue growing organically and through value-creating acquisitions.

Investor Relations Contact:

Seth Barker
Head of Investor Relations and VP of Financial Planning and Analysis
ir@perimetergroup.com

VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) — SHARC International Systems Inc. (CSE: SHRC) (FSE: IWIA) (OTCQB: INTWF) (“SHARC Energy” or the “Company”) is pleased to announce that, following a competitive procurement process, it has received a purchase order valued at over $5M from the City of Surrey for its District Energy Sewer Heat Recovery Project. The purchase order completed on October 22, 2026 is the largest in SHARC Energy’s history, approximately twice the size of the Company’s previous largest order. SHARC Energy will supply three SHARC 880 Wastewater Energy Transfer (“WET”) systems delivering 6 megawatts (“MW”) of thermal capacity to Surrey City Energy, the City’s district energy utility serving Surrey City Centre.

Purchase Order Highlights

Revenue from the project is expected to be generated in the second half of 2027 and into 2028, based on the current project schedule. The City is installing a multi system of  SHARC 880s to support a combined thermal capacity of 6 MW, processing approximately 12,000 litres of wastewater per minute. The facility is designed for phased expansion to approximately 27 MW as district energy demand grows, with any additional equipment subject to future procurement. With the project now secured by a purchase order, it will add over $5 million to the Company’s Sales Order Backlog in the fourth quarter of 2026, with the associated revenue subject to project delivery and performance of the Company’s contractual obligations.¹

The facility will recover thermal energy from a Metro Vancouver regional sewer main in Surrey’s Bridgeview neighbourhood. SHARC’s systems will screen the wastewater and transfer its heat to an ambient-temperature loop connecting to heat pumps at the West Village Energy Centre, approximately two kilometres away.

The City expects the facility to supply more than half of Surrey City Centre’s annual heating needs, reducing reliance on natural gas across a district energy network that already serves 49 buildings. The project is supported by the Government of Canada, the Province of British Columbia, Metro Vancouver and BC Hydro.

Equipment fabrication and delivery are planned for late 2027 to early 2028, followed by facility construction and commissioning under the City’s project schedule.

“This order is an important milestone for SHARC Energy, both in scale and in how we are developing our business,” said Shane Dungey, Interim Chief Executive Officer of SHARC Energy. “SHARC Energy is growing its business through direct relationships, as with the City of Surrey, and through its network of channel partners, to support its sales development objectives. Alongside executing this purchase order, our commercial focus will remain on customer engagement and disciplined management of the sales process.”

“Surrey’s project requires a system tailored to the scale and operating requirements of its district energy network,” said Michael Albertson, President of SHARC Energy. “The SHARC 880 platform allows us to configure our technology around those requirements, drawing on our experience supporting large wastewater energy recovery installations.”

Conceptual view of the proposed sewer heat recovery building, looking east from 110 Avenue, Surrey, B.C. Image: City of Surrey, District Energy Sewer Heat Recovery Project

Technology Designed for District Energy

For Surrey, SHARC Energy will integrate shell-and-tube heat exchangers with its wastewater screening, pumping and control systems to meet the project’s specifications. Its scope covers start-up, commissioning, operator training and technical support, backed by the remote monitoring and diagnostic capabilities of the SHARC platform.

With each SHARC system configured around the project’s wastewater, capacity and maintenance requirements, owners and engineers can incorporate wastewater heat recovery into both new and expanding district energy networks.

District Energy Sewer Heat Recovery Project location map: (1) sewer connection, pump station and sewer heat recovery facility in Bridgeview, where the SHARC systems will be installed; (2) approximately 2 km of underground heat distribution piping; (3) heat pump plant at the West Village Energy Centre in Surrey City Centre. Map: City of Surrey, District Energy Sewer Heat Recovery Project

Commercial Focus and Capital Planning

The Company aims to improve sales execution and retain a greater share of project economics, supporting its gross margin profile. This approach includes strengthening customer and channel partner engagement, disciplined project evaluation, and effective management of procurement, contracting and customer service processes.

“As we execute the Surrey project we are focused on aligning working capital and cash flow with project schedules.,” added Dungey. “We are working with third parties to explore capital solutions that can support delivery and sustainable growth.”

Building on an Established District Energy Portfolio

Surrey adds to SHARC Energy’s portfolio of major district energy projects, including Creative Energy’s Sen̓áḵw Energy System in Vancouver, the False Creek Neighbourhood Energy Utility, the National Western Center in Denver and the Alafia development in Brooklyn.

These projects reflect the application of wastewater energy recovery in individual buildings, community and district energy infrastructure. The City of Surrey order adds a multi-system installation to SHARC Energy’s district energy project portfolio, with modular and scalable configuration to meet the City’s sustainability goals.

Additional Project Information

Further information about the City’s project and contract award is available through:

• City of Surrey — District Energy Sewer Heat Recovery Project
• May 2026 City Council Corporate Report

¹ Sales Order Backlog is a non-IFRS measure. Please refer to the discussion of Alternative Performance Measures and Non-IFRS Measures in the Company’s Q2 2026 MD&A.

About SHARC Energy

SHARC International Systems Inc. is a leader in recovering thermal energy from the wastewater we send down the drain every day. SHARC Energy’s systems recycle this energy for heating, cooling and hot water production in commercial, residential and industrial buildings, as well as thermal energy networks commonly referred to as district energy.

SHARC Energy is publicly traded in Canada (CSE: SHRC), the United States (OTCQB: INTWF) and Germany (Frankfurt: IWIA). Additional Company information is available through its SEDAR+ profile.

Learn more about SHARC Energy: Website | Investor Page | LinkedIn | YouTube | PIRANHA | SHARC

ON BEHALF OF THE BOARD

Fred Andriano
Chairman

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Certain statements contained in this news release constitute forward-looking information. Forward-looking information is often, but not always, identified by words such as “anticipate,” “plan,” “estimate,” “expect,” “may,” “will,” “intend,” “should” and similar expressions.

Forward-looking information in this release includes statements regarding the expected revenue from the purchase order and timing of revenue recognition; its addition to the Company’s Sales Order Backlog; fabrication, delivery, construction, commissioning and operation of the facility; anticipated thermal capacity and contribution to Surrey City Centre’s heating needs; potential future facility expansion; expected improvements in the project’s gross margin profile; the Company’s direct sales strategy and pipeline development; anticipated project announcements before year-end; and potential financing and other capital solutions.

These statements are based on the Company’s current expectations and assumptions, including execution of the purchase order, the current project schedule, anticipated project costs, availability of equipment and materials, coordination with the City of Surrey and its contractors, completion of customer procurement and contracting processes, and access to suitable capital arrangements. The project schedule is controlled in part by third parties and may change.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated. These include changes to project scope or timing, procurement and production delays, cost increases, customer decisions, availability and terms of financing, regulatory decisions, competitive factors, prevailing economic conditions and other factors beyond the Company’s control.

SHARC Energy believes the expectations reflected in this forward-looking information are reasonable, but no assurance can be given that they will prove correct. Such information should not be unduly relied upon. Forward-looking information represents the Company’s expectations as of the date of this release. The Company disclaims any intention or obligation to update or revise it, except as required by applicable securities legislation.

¹ Sales Order Backlog is a non-IFRS measure. Please refer to the discussion of Alternative Performance Measures and Non-IFRS Measures in the Company’s Q2 2026 MD&A.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/4f998a33-466c-4f52-bf50-988becf251ac
https://www.globenewswire.com/NewsRoom/AttachmentNg/c997b38a-a7b7-4319-8530-611ea6c1c531

CONTACT: For investor inquiries, please contact:

SHARC International Systems Inc.
Telephone: +1 (604) 475-7710
Email: ir@sharcenergy.com
Website: www.sharcenergy.com

For media inquiries, please contact:

John Louis Fahie
Marketing Director
SHARC Energy
Telephone: 604.475.7710 Ext. 109
Email: johnlouis.fahie@sharcenergy.com

TORTOLA, British Virgin Islands, Oct. 22, 2026 (GLOBE NEWSWIRE) — Orca Energy Group Inc. (“Orca” or the “Company”) (TSX-V: ORC.A, ORC.B) announces that Taifa Gas Tanzania Limited and Amber Energy Investment L.L.C-FZ (the “Purchasers”) have appealed the decision of the Fair Competition Commission of Tanzania (the “FCC”) prohibiting the Company’s previously announced proposed transaction (the “Proposed Transaction”) with the Purchasers.

As previously disclosed, Orca entered into the Proposed Transaction through a Sale and Purchase Agreement with the Purchasers on April 10, 2026, pursuant to which Orca agreed to sell all of the outstanding shares of PAE PanAfrican Energy Corporation, Orca’s Mauritian holding subsidiary, through which Orca indirectly owns PanAfrican Energy Tanzania Limited (“PAET”). On October 5, 2026, the FCC issued a notice to PAET and the Purchasers prohibiting the merger application relating to the Proposed Transaction. On October 15, 2026, the FCC provided PAET and the Purchasers the reasons for prohibiting the Proposed Transaction (the “FCC Decision”). Following review of the FCC Decision and discussions among the Company, PAET, and the Purchasers, on October 20, 2026, the Purchasers filed an appeal of the FCC Decision with the Fair Competition Tribunal of Tanzania, the appellate body responsible for reviewing FCC rulings.

The Proposed Transaction has not been terminated, and remains subject to specific and customary closing conditions, including approval of the TSX Venture Exchange.

About Orca Energy Group Inc.

Orca is an international public company engaged in natural gas exploration, development and supply in Tanzania through its subsidiary PanAfrican Energy Tanzania Limited. Orca trades on the TSX Venture Exchange under the trading symbols ORC.A and ORC.B.

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CONTACT: For further information please contact:
Jay Lyons
Chief Executive Officer
+44 (0)20 8434 2754
ir@orcaenergygroup.com

David W. Ross

Chair and Non-Executive Director
+1 (403) 830-2455
dross7915@gmail.com

For media enquiries:
Celicourt (PR)
Mark Antelme
Orca@celicourt.uk
+44-20 8434 2643

SEATTLE, Oct. 22, 2026 (GLOBE NEWSWIRE) — Banzai International, Inc. (NASDAQ: PARA) (d/b/a “Parabolic” or the “Company”), a leading AI-powered agentic applications technology company, today announced that effective at market open on October 27, 2026, the Company’s corporate name will officially change to “Parabolic Technologies, Inc.” The Company will also effect a one-for-ten (1-for-10) reverse stock split of its outstanding Class A Common Stock and Class B Common Stock (together, the “Common Stock”).

Shareholders approved both the corporate name change and reverse stock split at a special meeting of shareholders that was held on October 16, 2026. 

The reverse stock split is primarily intended to increase the per share price of the Company’s Class A Common Stock and maintain compliance with the Nasdaq Minimum Bid Price Requirement, although neither outcome is guaranteed. The Company’s Class A Common Stock will continue to trade under the symbol “PARA”. Upon the effectiveness of the reverse stock split, every ten shares of issued and outstanding Common Stock before the open of business on October 27, 2026, will be combined into one issued and outstanding share of common stock, with no change in par value per share. The Company’s Class A Common Stock will open for trading on Nasdaq on October 27, 2026, on a post-split basis but will trade under a new CUSIP Number, 06682J803.

As of October 21, 2026, there were 5,061,208 shares of Class A Common Stock and 149,821 shares of Class B Common Stock outstanding. The number of issued and outstanding shares of Common Stock after the reverse stock split would be approximately 506,121 and 14,983 shares of Class A Common Stock and Class B Common Stock, respectively. No fractional shares will be issued as a result of the reverse stock split. Any fractional shares that would result from the reverse stock split will be rounded up to the nearest whole share.

The reverse stock split will affect all issued and outstanding shares of the Company’s Common Stock, as well as the number of shares of Common Stock available for issuance under the Company’s stock options and warrants. In addition, the reverse stock split will correspondingly increase the respective aggregate exercise prices of our outstanding options and warrants. The reverse stock split will affect all holders of Common Stock uniformly and will not alter any shareholder’s percentage interest in the Company’s Common Stock, except to the extent that the reverse stock split results in some shareholders experiencing an adjustment of a fractional share as described above.

Shareholders holding share certificates will receive information from Continental Stock Transfer & Trust Company, the Company’s transfer agent, regarding the process for exchanging their existing stock certificates representing pre-split shares; shareholders need not take any action with respect to the Name Change. Shareholders with questions may contact our transfer agent by calling 800-509-5586.

About Parabolic

Parabolic builds agentic applications that power the future of business. We believe that the future of enterprise software will be agentic applications that are net-beneficiaries of AI transformation, and we focus on building, acquiring, and investing in those and related businesses. We have over 150,000 customers including Amazon, Dell, Salesforce, Aflac, Thermo Fisher Scientific, RBC Wealth Management, and Fitch Group. Learn more at www.parabolic.io. For investors, please visit ir.banzai.io.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often use words such as “believe,” “may,” “will,” “estimate,” “target,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “propose,” “plan,” “project,” “forecast,” “predict,” “potential,” “seek,” “future,” “outlook,” and similar variations and expressions. Forward-looking statements are those that do not relate strictly to historical or current facts. Examples of forward-looking statements may include, among others, statements regarding Banzai International, Inc.’s (the “Company’s”): future financial, business and operating performance and goals; annualized recurring revenue and customer retention; ongoing, future or ability to maintain or improve its financial position, cash flows, and liquidity and its expected financial needs; potential financing and ability to obtain financing; acquisition strategy and proposed acquisitions and, if completed, their potential success and financial contributions; strategy and strategic goals, including being able to capitalize on opportunities; expectations relating to the Company’s industry, outlook and market trends; total addressable market and serviceable addressable market and related projections; plans, strategies and expectations for retaining existing or acquiring new customers, increasing revenue and executing growth initiatives; and product areas of focus and additional products that may be sold in the future. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity and development of the industry in which the Company operates may differ materially from those made in or suggested by the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements. Factors that may cause actual results to differ materially include changes in the markets in which the Company operates, customer demand, the financial markets, economic, business and regulatory and other factors, such as the Company’s ability to execute on its strategy. More detailed information about risk factors can be found in the Company’s Annual Report on Form 10-K and the Company’s Quarterly Reports on Form 10-Q under the heading “Risk Factors,” and in other reports filed by the Company, including reports on Form 8-K. The Company does not undertake any duty to update forward-looking statements after the date of this press release.

Investor Relations
Dean Ditto
Chief Financial Officer
206 414-1777
ir.banzai.io

Media
Paul Witkowski
Senior Director Financial Reporting
media@parabolic.io

Nes-Ziona, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) — Enlivex Ltd. (Nasdaq: ENLV) (“Enlivex” or the “Company”), a quality longevity company powered by a prediction markets treasury, today announced a 1-for-16 reverse split (the “Reverse Split”) of its ordinary shares, which will become effective on October 27, 2026, on which date the Company’s ordinary shares will trade on The Nasdaq Capital Market on a split-adjusted basis.

As a result of the Reverse Split, every 16 ordinary shares will automatically be combined into one ordinary share. Upon effectiveness of the Reverse Split, the number of authorized ordinary shares will be ratably reduced from 158,333,333 to 9,895,833, and the par value of each ordinary share will ratably increase from NIS 6.00 to NIS 96.00. Additionally, upon effectiveness of the Reverse Split, the number of Enlivex’s issued and outstanding ordinary shares will decrease from 24,511,905 to approximately 1,531,995, subject to adjustment based on the rounding of fractional shares.

No fractional ordinary shares will be issued as a result of the Reverse Split. All fractional shares will be rounded up to the nearest whole ordinary share. In addition, a proportionate adjustment will be made to the per share exercise price and the number of shares issuable upon the exercise of all of Enlivex’s outstanding warrants and options. The Reverse Split will not affect any shareholder’s ownership percentage of the ordinary shares (except for adjustments that may result from the rounding up of fractional shares) or modify any voting rights or other terms of the ordinary shares.

The Company’s ordinary shares will continue to trade on The Nasdaq Capital Market under the symbol “ENLV”. The new CUSIP number for the ordinary shares following the Reverse Split will be M4130Y205.

The Company’s transfer agent, VStock Transfer, LLC, is acting as exchange agent for the Reverse Split and will send instructions to shareholders of record regarding the exchange of certificates for ordinary shares.

About Enlivex (Nasdaq: ENLV)

Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “would,” “could,” “intends,” “estimates,” “suggests,” “target,” “has the potential to,” “goal,” “on track,” and other words of similar meaning, including statements relating to the Company’s cost reduction plan, including the expected reductions in operating expenses and cash burn, the expected timing and amount of related restructuring charges, and the Company’s ability to fund its operations; the Company’s need for, and ability to obtain, additional financing; the progress, enrollment, design and expected timing of completion of the Company’s Phase 2b clinical trial of ALLOCETRA™; the expected timing of topline six-month data from the Phase 2b trial; the potential benefits of RMAT designation; the anticipated benefits of the Company’s digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the Company’s plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk that the cost reduction plan may not achieve the anticipated savings, may take longer than expected to implement, or may result in unanticipated costs or disruptions, including to the conduct of the Phase 2b trial; the risk that the Company will be unable to obtain additional financing on acceptable terms, or at all, to fund the Phase 2b trial through topline data; risks related to the timing of patient enrollment and the conduct, completion and results of clinical trials; the risk that results of earlier clinical trials, including the Phase 1/2a trial, may not be predictive of results of later trials, including the Phase 2b trial; the risk that RMAT designation may not result in a faster development or regulatory review process and does not increase the likelihood of regulatory approval; the risk that the Company may not obtain regulatory approval for ALLOCETRA™ on the anticipated timeline or at all; the risk of failure to realize the anticipated benefits of the Company’s digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; the risk that the price and liquidity of the Company’s ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.

ENLIVEX CONTACT
Shachar Shlosberger, CFO
Enlivex Ltd.
shachar@enlivex.com

KHOU becomes a founding marketing partner as the four-time WNBA champion Comets return home

MCLEAN, Va. and HOUSTON, Oct. 22, 2026 (GLOBE NEWSWIRE) — TEGNA Inc. (NASDAQ: NXST) and the Houston Comets today announced a multi-year partnership, making KHOU and KTBU the local broadcast home of the Comets. Starting with the team’s 2027 season, locally available Comets games will air free over-the-air on KTBU, with select games simulcast on KHOU, TEGNA’s CBS affiliate in Houston. The games will also be simulcast on Space City Home Network, the team’s regional sports network, and on SCHN+, the direct-to-consumer streaming service.

As a founding marketing partner for the team, KHOU will create new and exclusive Comets content year-round, providing coverage across its newscasts, 24/7 streaming channel and digital platforms. KHOU and TEGNA will also play a key role in advertising and sponsorship sales for the team’s broadcasts on the stations.

“The Comets’ return to Houston is a big moment for the city, and we’re proud to be part of it,” said Brad Ramsey, senior vice president and head of sports rights, TEGNA. “This partnership expands our WNBA footprint and lets us connect the team with the community, bringing fans closer to the Comets on and off the court, all year.”

“Bringing the Comets back to Houston is about reigniting the passion, pride and energy that have always connected this organization with its fans and community,” said Gretchen Sheirr, President of Business Operations for the Houston Rockets and Comets. “As the WNBA continues to reach new heights, we’re thrilled to partner with TEGNA to make Comets basketball more accessible to fans across the Houston area through free, over-the-air broadcasts on KTBU and additional coverage on KHOU. We’re excited to bring fans closer to the action and deliver outstanding coverage as we begin this exciting new chapter in Comets history.”

One of the WNBA’s original eight franchises, the Comets won the league’s first four championships and helped create the early identity and success of the league. Houston’s return to the WNBA comes during a period of extraordinary momentum for the league, which plans to expand to 18 teams by 2030.

“KHOU has covered Houston sports for decades, and the Comets’ homecoming is a story we’ve been waiting to tell,” said David Loving, president and general manager, KHOU. “As a founding partner, we’re ready to bring Comets action to fans across the region.”

How to watch:

• KTBU (channel 55): Every locally available game airs live on KTBU.
• KHOU 11: Select games each season are simulcast on KHOU.
• Over the air: Fans can watch for free with an antenna.
• On Space City Home Network and SCHN+ streaming service.

About TEGNA
TEGNA Inc. is a wholly owned subsidiary of Nexstar Media Group, Inc. (NASDAQ: NXST), operating independently of Nexstar consistent with the Hold Separate Order issued by the United States District Court for the Eastern District of California on April 17, 2026. TEGNA is a multiplatform media company operating 64 local television stations in 51 U.S. markets, and hundreds of websites, mobile and Connected TV (CTV) apps, and Premion, a leading Connected TV and Over-the-Top (OTT) advertising platform.

For TEGNA media inquiries, contact: 
Molly McMahon
Sr. Director, Corporate Communications
703-873-6422
mmcmahon@tegna.com

For Houston Comets media inquiries, contact: 
Tracey Hughes
Vice President of Communications
Houston Rockets | Houston Comets | Toyota Center
713-758-7335
traceyh@rocketball.com